Nanologica AB (publ) (NICA) Q3 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome to RedEye and today's interview with Andreas Bagwani, who is the CEO of Analogica, who has recently released his quarterly report. Welcome, Andreas. Thank you. I think we'll dive straight into the report. Can you briefly go through what the most important points are in the report? I would say there are three factors. The first is that we again have production that works. We had that last quarter as well. It is extremely important for us that we have a production that is stable and works. We are not satisfied with it, but it works and gives great products. The second is that after the period started, we took another order to the same customer as a GLP-1 customer. That's the second most important thing. And then we got money from a company that I also put my share in. That's the third thing. Right. And in the report you talk a little bit about warehouse construction and it costs a lot of money. Can you talk a little bit about how much warehouse are you going to build here in the near future and what is the baseline level where you think you will be? That's a good question. When we produce, we produce a little different products. So now we have some products on the shelf that are mainly for insulin customers and we haven't really started there. What we are producing now is mainly for GLP-1 customers. It's almost the same product, a little different. And there we think that the warehouse construction will be very low because there we will probably sell it as soon as we have produced it. So I don't think that the level we have now will decrease, but it will probably increase, but perhaps not so quickly. And as you mentioned, you have some different product variants in the law. Can you just briefly describe a little more about these differences? When you produce ou...